| Document |
Document Title |
|
WO/2024/025465A1 |
Disclosed herein are methods of obtaining ferulic acid. In one aspect, the present disclosure refers to a method of hydrolysing oryzanol to obtain ferulic acid, wherein the method comprises: i. hydrolysing an oryzanol-comprising material...
|
|
WO/2023/241877A1 |
The present invention relates to a process for the preparation of a budesonide intermediate, in particular the compound of formula (I).
|
|
WO/2021/194244A1 |
The present invention relates to a novel method for preparing Inotodiol. The method differs in terms of process from existing methods for preparing Inotodiol, and produces a high yield of Inotodiol. Therefore, the method can be useful fo...
|
|
WO/2021/142477A1 |
The invention of this disclosure is directed to a neuroactive steroid (NAS) of a novel structure. This invention is also directed to a pharmaceutical composition comprising the neuroactive steroid (NAS) and salts thereof. The pharmaceuti...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/082065A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...
|
|
WO/2020/077255A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/113494A1 |
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...
|
|
WO/2019/106865A1 |
Provided are: an acyl novel steryl glucoside; and a method for producing an acyl steryl glucoside by using labyrinthula as a raw material. This acyl steryl glucoside is represented by structural formula (I), structural formula (II), or s...
|
|
WO/2019/024920A1 |
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, ...
|
|
WO/2017/199033A1 |
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...
|
|
WO/2017/199039A1 |
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
|
WO/2016/044559A1 |
The present invention relates to C-20 steroid compounds, compositions and methods of use thereof to treat, minimize and/or prevent traumatic brain injury (TBI), including severe TBI, moderate TBI and mild TBI, including concussions.
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2016/004910A1 |
The solution relates to a method of preparing abiraterone acetate of formula I, which comprises: a) preparation of abiraterone of formula II by the Suzuki reaction of 3-pyridyldiethylborane and a halo steroid of formula VI or VII in the ...
|
|
WO/2014/207762A1 |
The present invention relates to improvement in the process of preparation of abiraterone acetate or a pharmaceutically acceptable salt thereof wherein the improvement comprises purifying the crude 3-&-acetoxyandrosta-5,16-diene-17-yl tr...
|
|
WO/2014/083512A1 |
The present invention relates to process for the preparation of abiraterone acetate, its salts and intermediates thereof, crystalline forms of abiraterone acetate salts and purification of abiraterone acetate.
|
|
WO/2014/058736A1 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the tre...
|
|
WO/2013/089595A1 |
The invention relates to the chemistry of natural and physiologically active substances and more particularly to a process for obtaining an intermediate product in the synthesis of steroid hormones of the pregnane series. The targeted ta...
|
|
WO/2013/053691A1 |
The present invention relates to a process for the preparation of 17-substituted steroids and, more particularly, to an improved method of synthesizing abiraterone or derivatives thereof in high yield and purity by means of a key 3-forma...
|
|
WO/2012/164096A1 |
The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of : a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of f...
|
|
WO/2012/127176A1 |
The present invention relates to novel neurosteroids, especially derivatives of allopregnanolone and of epiallopregnanolone of formula (I) and the uses thereof as medicament for the treatment of neuropathologies, in particular neuropathi...
|
|
WO/2012/118068A1 |
The present invention relates to substance 3787-5-1 represented by formula (I) and pharmaceutically permissible salts thereof. Substance 3787-5-1 is useful for the prevention and treatment of a disease caused by a cell proliferative diso...
|
|
WO/2012/063794A1 |
This method for producing an oil or fat that contains γ-oryzanol is characterized by comprising: a step (A) for obtaining a treated oil or fat product having an oil layer and an alkaline oil cake layer containing an γ-oryzanol salt; an...
|
|
WO/2009/122435A2 |
The present invention relates to preparation and biological evaluation of 3-acetoxy-17- acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2'-chloro-5-androsteno [17,16- b]pyridine (5) as gastric proton pump inhibitor and their comp...
|
|
WO/2009/100723A2 |
Crystalline forms of 24-bromofusidic acid, their preparation, pharmaceutical compositions containing them, and the use of said crystalline 24-bromofusidic acid forms as medicaments in the treatment of infectious diseases.
|
|
WO/2009/096445A1 |
Disclosed are a neural stem cell propagation accelerator which contains a compound produced by Penicillium sp. strain CND1007 (FERM BP-10917) or a pharmacologically acceptable salt thereof, a novel compound produced by Penicillium sp. st...
|
|
WO/2009/035527A2 |
The present invention provides for a crystalline polymorph of levonorgestrel and processes for making the same.
|
|
WO/2008/157635A2 |
Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
|
|
WO/2008/110941A2 |
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor like 24-substituted oxy-7-substitutedoxycholestan-3- one, preferably of 24β-benzoyloxy-7α-hydroxycholestan-3-one.
|
|
WO/2008/012833A1 |
The present invention provides an improved process for the preparation of 16-dehydropregenolone acetate [16-DPA], wherein pseudodiosgenin diacetate (PDA) is oxidized to diosone by catalytic amount of KMnO4 in the presence of a co oxidant...
|
|
WO/2007/051468A2 |
The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medica...
|
|
WO2005077968B1 |
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...
|
|
WO/2005/049634A1 |
A compound of formula (I), wherein R has various meaning and its use as a pharmaceutical.
|
|
WO/2005/042422A2 |
An optical fiber, and a method of making such optical fiber, wherein the optical fiber exhibits a beatlength greater than about 0.5 meters, and the fiber is spun to provide a polarization mode dispersion in the spun state of said fiber w...
|
|
WO2002042319A9 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
WO/2005/007669A1 |
The present Invention relates to novel fusidic acid derivatives of general formula (I) wherein X represents halogen, trifluoromethyl, cyano, azido, alkyl, alkenyl or aryl, wherein. said alkyl, alkenyl or aryl are optionally substituted b...
|
|
WO/2004/094450A1 |
The present invention relates to a method for selective preparing 4,17 (20)-E-pregnadiene-3,16-dione (E-guggulsterone) of the formula (III) and 4,17 (20)-Z-pregnadiene-3,16-dione (Z-guggulsterone) of the formula (IV) having an effect of ...
|
|
WO/2004/091474A2 |
The invention relates to a method for the production of DHEA derivatives, such as 7-oxo-DHEA and 7-hydroxy-DHEA, from DHEA itself.
|
|
WO/2004/060906A1 |
The present invention provides an improved process for the preparation of Guggulsterones which comprises epoxidising 16-dihydropegnenolone acetate (16 DPA) by reacting 16DPA with hydrogen peroxide reagent adduct in the presence of a co-b...
|
|
WO/2003/020744A1 |
Novel 17-methylene-4-azasteroids of general formula (I), where R?20¿ and R?20a¿ independently = fluoro, chloro, bromo and cyano groups; R?4¿ and R?10¿ = H or methyl; R?1¿ and R?2¿ = each an H atom or together an additional bond, ar...
|
|
WO/2002/070537A2 |
Novel 17,20-methanofusidic acid derivatives are used in pharmaceutical compositions for the treatment of infections, in particular in topical compositions for the treatment of skin or eye infections.
|
|
WO2002019971A9 |
The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as...
|
|
WO/2002/000681A1 |
The invention related to 20$g(j)-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester, 20$g(j)-fluoro-3$g(b)-hydroxypregna-4,17(20)-dien-21-oic acid ethyl ester, 20$g(j)-fluoro-21-hydroxypregna-4,17(20)-dien-3-one, 20$g(j)-fluoropregn...
|
|
WO/2001/085755A1 |
Compounds of formula (I) in which: R?1¿ represents a hydrogen atom or an O-protecting group; R?2¿ represents a hydroxyl, lower alkoxy, carboxaldehyde, lower alk-1-enyl or hydroxy- or lower alkoxy-substituted lower alkyl group; R?3¿ re...
|
|
WO/2001/060836A1 |
A process for the preparation of a 3-alkoxy- 1,3,5(10)-trien-6-one-steroid derivative having a partial structure of the general formula (2) as the moiety corresponding to the rings A and B of steroidal skeleton: (2) (wherein R is alkyl, ...
|
